{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:39Z","timestamp":1792787979183,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Naslund Medical AB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15041-8","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:32:11Z","timestamp":1761809531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stereotactic body radiation therapy for inoperable non-metastasized pancreatic adenocarcinoma: a randomised phase II study (TORPEDO)."],"prefix":"10.1186","volume":"25","author":[{"given":"Daan","family":"Stas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timon","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Roeyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dries","family":"Reynders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Demey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Stellamans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bussels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Hutsebaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Maurissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Bouchart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Berb\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Lallemand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Poels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter-Jan","family":"Cuyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bulens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katleen","family":"Verboven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhilde","family":"Weytjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Joye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"1","key":"15041_CR1","first-page":"12","volume":"74","author":"R Siegel","year":"2024","unstructured":"Siegel R, Giaquinto A, Jemal A. Cancer statistics 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"15041_CR2","unstructured":"Cancer fact. sheet 2022: pancreatic cancer 2022 [Available from: https:\/\/kankerregister.org\/sites\/default\/files\/2024\/20241015_BE_CFS_PANCREAS_V1.pdf"},{"key":"15041_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Pancreatic adenocarcinoma 2025 [updated 03\/02\/2025. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf"},{"issue":"19","key":"15041_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"6","key":"15041_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801\u201310.","journal-title":"Lancet Oncol"},{"issue":"11","key":"15041_CR6","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1245\/s10434-015-4647-4","volume":"22","author":"E Sadot","year":"2015","unstructured":"Sadot E, Doussot A, O\u2019Reilly EM, Lowery MA, Goodman KA, Do RK, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(11):3512\u201321.","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"15041_CR7","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO-24-02210","volume":"43","author":"M Ducreux","year":"2025","unstructured":"Ducreux M, Desgrippes R, Rinaldi Y, Di Fiore F, Guimbaud R, Evesque L, et al. PRODIGE 29-UCGI 26 (NEOPAN): A phase III randomized trial comparing chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic carcinoma. J Clin Oncol. 2025;43(20):2255\u201364.","journal-title":"J Clin Oncol"},{"issue":"11","key":"15041_CR8","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","volume":"27","author":"CA Iacobuzio-Donahue","year":"2009","unstructured":"Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806\u201313.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15041_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ijrobp.2015.11.003","volume":"94","author":"KW Merrell","year":"2016","unstructured":"Merrell KW, Haddock MG, Quevedo JF, Harmsen WS, Kendrick ML, Miller RC, et al. Predictors of locoregional failure and impact on overall survival in patients with resected exocrine pancreatic cancer. Int J Radiat Oncol Biol Phys. 2016;94(3):561\u201370.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"15041_CR10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844\u201353.","journal-title":"JAMA"},{"issue":"12","key":"15041_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa032295","volume":"350","author":"JP Neoptolemos","year":"2004","unstructured":"Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200\u201310.","journal-title":"N Engl J Med"},{"issue":"6","key":"15041_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","volume":"16","author":"JY Chang","year":"2015","unstructured":"Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630\u20137.","journal-title":"Lancet Oncol"},{"issue":"4","key":"15041_CR13","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"104","author":"WC Jackson","year":"2019","unstructured":"Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, et al. Stereotactic body radiation therapy for localized prostate cancer: A systematic review and Meta-Analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019;104(4):778\u201389.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"15041_CR14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ijrobp.2003.11.004","volume":"58","author":"AC Koong","year":"2004","unstructured":"Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58(4):1017\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"21","key":"15041_CR15","doi-asserted-by":"publisher","first-page":"7879","DOI":"10.1002\/cam4.3330","volume":"9","author":"A Arcelli","year":"2020","unstructured":"Arcelli A, Buwenge M, Macchia G, Bertini F, Guido A, Deodato F, et al. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1). Cancer Med. 2020;9(21):7879\u201387.","journal-title":"Cancer Med"},{"issue":"21","key":"15041_CR16","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.30856","volume":"123","author":"SWL de Geus","year":"2017","unstructured":"de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, Mancias JD, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer. 2017;123(21):4158\u201367.","journal-title":"Cancer"},{"issue":"18","key":"15041_CR17","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1002\/cncr.30706","volume":"123","author":"J Zhong","year":"2017","unstructured":"Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, et al. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123(18):3486\u201393.","journal-title":"Cancer"},{"issue":"10","key":"15041_CR18","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/cncr.32756","volume":"126","author":"LT Tchelebi","year":"2020","unstructured":"Tchelebi LT, Lehrer EJ, Trifiletti DM, Sharma NK, Gusani NJ, Crane CH, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis. Cancer. 2020;126(10):2120\u201331.","journal-title":"Cancer"},{"issue":"12","key":"15041_CR19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1586\/14737140.2014.952286","volume":"14","author":"S Moningi","year":"2014","unstructured":"Moningi S, Marciscano AE, Rosati LM, Ng SK, Teboh Forbang R, Jackson J, et al. Stereotactic body radiation therapy in pancreatic cancer: the new frontier. Expert Rev Anticancer Ther. 2014;14(12):1461\u201375.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"15041_CR20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","volume":"270","author":"G Gemenetzis","year":"2019","unstructured":"Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340\u20137.","journal-title":"Ann Surg"},{"key":"15041_CR21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","volume":"155","author":"MA Teriaca","year":"2021","unstructured":"Teriaca MA, Loi M, Suker M, Eskens F, van Eijck CHJ, Nuyttens JJ. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. Radiother Oncol. 2021;155:232\u20136.","journal-title":"Radiother Oncol"},{"issue":"5","key":"15041_CR22","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.surg.2020.10.044","volume":"169","author":"CR Ferrone","year":"2021","unstructured":"Ferrone CR. Divestment\/skeletonization of the arteries in patients with advanced pancreatic ductal cancer. Surgery. 2021;169(5):1037\u20138.","journal-title":"Surgery"},{"issue":"7","key":"15041_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","volume":"54","author":"EA Mellon","year":"2015","unstructured":"Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54(7):979\u201385.","journal-title":"Acta Oncol"},{"key":"15041_CR24","doi-asserted-by":"publisher","first-page":"100200","DOI":"10.1016\/j.eclinm.2019.10.013","volume":"17","author":"M Suker","year":"2019","unstructured":"Suker M, Nuyttens JJ, Eskens F, Haberkorn BCM, Coene PLO, van der Harst E, et al. Efficacy and feasibility of stereotactic radiotherapy after Folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). EClinicalMedicine. 2019;17:100200.","journal-title":"EClinicalMedicine"},{"key":"15041_CR25","doi-asserted-by":"crossref","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346.","DOI":"10.1136\/bmj.e7586"},{"issue":"2","key":"15041_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"15041_CR27","unstructured":"https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/08\/Specimen-QLQ-C30-English.pdf"},{"key":"15041_CR28","unstructured":"https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/08\/Specimen-PAN26-English.pdf"},{"issue":"2","key":"15041_CR29","doi-asserted-by":"publisher","first-page":"E253","DOI":"10.1055\/a-1324-2892","volume":"9","author":"M Figueiredo","year":"2021","unstructured":"Figueiredo M, Bouchart C, Moretti L, Mans L, Engelholm JL, Bali MA, et al. EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score. Endosc Int Open. 2021;9(2):E253\u20137.","journal-title":"Endosc Int Open"},{"key":"15041_CR30","first-page":"100797","volume":"47","author":"H Grimbergen","year":"2024","unstructured":"Grimbergen H, Eijkelenkamp H, Snoeren L, Bahij R, Bernchou U, van der Bijl E, et al. Treatment planning for MR-guided SBRT of pancreatic tumors on a 1.5 T MR-Linac: A global consensus protocol. Clin Transl Radiat Oncol. 2024;47:100797.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"15041_CR31","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.prro.2019.07.018","volume":"10","author":"A Oar","year":"2020","unstructured":"Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, et al. Australasian Gastrointestinal trials group (AGITG) and Trans-Tasman radiation oncology group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT). Pract Radiat Oncol. 2020;10(3):e136\u201346.","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"15041_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.prro.2016.10.006","volume":"7","author":"HD Heerkens","year":"2017","unstructured":"Heerkens HD, Hall WA, Li XA, Knechtges P, Dalah E, Paulson ES, et al. Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. Pract Radiat Oncol. 2017;7(2):126\u201336.","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"15041_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","volume":"34","author":"P Diez","year":"2022","unstructured":"Diez P, Hanna GG, Aitken KL, van As N, Carver A, Colaco RJ, et al. UK 2022 consensus on normal tissue Dose-Volume constraints for Oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy. Clin Oncol (R Coll Radiol). 2022;34(5):288\u2013300.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"15041_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.21873\/anticanres.13975","volume":"40","author":"A Arcelli","year":"2020","unstructured":"Arcelli A, Guido A, Buwenge M, Simoni N, Mazzarotto R, Macchia G, et al. Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1). Anticancer Res. 2020;40(1):465\u201372.","journal-title":"Anticancer Res"},{"issue":"8","key":"15041_CR35","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/j.tranon.2021.101139","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S, Liu Y, Yang J, Santos TD, Yang L, Li M, et al. Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis. Transl Oncol. 2021;14(8):101139.","journal-title":"Transl Oncol"},{"key":"15041_CR36","doi-asserted-by":"crossref","unstructured":"Lin T, Reddy A, Hill C, Sehgal S, He J, Zheng L et al. The timing of surgery following stereotactic body radiation therapy impacts local control for borderline resectable or locally advanced pancreatic cancer. Cancers (Basel). 2023;15(4).","DOI":"10.3390\/cancers15041252"},{"key":"15041_CR37","unstructured":"https:\/\/www.kwf.nl\/onderzoek\/onderzoeksdatabase\/chirurgie-versus-stereotactische-ablatieve-radiotherapie-mri-geleid-in"},{"key":"15041_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.radonc.2020.07.053","volume":"152","author":"DAS Toesca","year":"2020","unstructured":"Toesca DAS, Ahmed F, Kashyap M, Baclay JRM, von Eyben R, Pollom EL, et al. Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Radiother Oncol. 2020;152:63\u20139.","journal-title":"Radiother Oncol"},{"issue":"1","key":"15041_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/COC.0000000000000472","volume":"42","author":"NG Zaorsky","year":"2019","unstructured":"Zaorsky NG, Lehrer EJ, Handorf E, Meyer JE. Dose escalation in stereotactic body radiation therapy for pancreatic cancer: A Meta-Analysis. Am J Clin Oncol. 2019;42(1):46\u201355.","journal-title":"Am J Clin Oncol"},{"key":"15041_CR40","doi-asserted-by":"publisher","first-page":"175883592110458","DOI":"10.1177\/17588359211045860","volume":"13","author":"C Bouchart","year":"2021","unstructured":"Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gokburun Y, et al. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma. Ther Adv Med Oncol. 2021;13:17588359211045860.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"15041_CR41","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.ijrobp.2014.06.066","volume":"90","author":"EL Pollom","year":"2014","unstructured":"Pollom EL, Alagappan M, von Eyben R, Kunz PL, Fisher GA, Ford JA, et al. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys. 2014;90(4):918\u201325.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15041_CR42","doi-asserted-by":"crossref","unstructured":"Kamel R, Dennis K, Doody J, Pantarotto J. Ablative vs. Non-Ablative radiotherapy in palliating locally advanced pancreatic cancer: A single institution experience and a systematic review of the literature. Cancers (Basel). 2023;15(11).","DOI":"10.3390\/cancers15113016"},{"issue":"4","key":"15041_CR43","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.ijrobp.2012.07.2366","volume":"85","author":"CM Taniguchi","year":"2013","unstructured":"Taniguchi CM, Murphy JD, Eclov N, Atwood TF, Kielar KN, Christman-Skieller C, et al. Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85(4):1090\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15041_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1748-717X-9-11","volume":"9","author":"W Yang","year":"2014","unstructured":"Yang W, Fraass BA, Reznik R, Nissen N, Lo S, Jamil LH, et al. Adequacy of inhale\/exhale breathhold CT based ITV margins and image-guided registration for free-breathing pancreas and liver SBRT. Radiat Oncol. 2014;9:11.","journal-title":"Radiat Oncol"},{"key":"15041_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.phro.2022.02.007","volume":"21","author":"S Alam","year":"2022","unstructured":"Alam S, Veeraraghavan H, Tringale K, Amoateng E, Subashi E, Wu AJ, et al. Inter- and intrafraction motion assessment and accumulated dose quantification of upper Gastrointestinal organs during magnetic resonance-guided ablative radiation therapy of pancreas patients. Phys Imaging Radiat Oncol. 2022;21:54\u201361.","journal-title":"Phys Imaging Radiat Oncol"},{"key":"15041_CR46","doi-asserted-by":"publisher","first-page":"1298099","DOI":"10.3389\/fonc.2023.1298099","volume":"13","author":"DN Rusu","year":"2023","unstructured":"Rusu DN, Cunningham JM, Arch JV, Chetty IJ, Parikh PJ, Dolan JL. Impact of intrafraction motion in pancreatic cancer treatments with MR-guided adaptive radiation therapy. Front Oncol. 2023;13:1298099.","journal-title":"Front Oncol"},{"issue":"1","key":"15041_CR47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13014-022-02076-5","volume":"17","author":"M Vornhulz","year":"2022","unstructured":"Vornhulz M, Anton S, Eross B, Szakacs Z, Hegyi P, Regel I, et al. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review. Radiat Oncol. 2022;17(1):108.","journal-title":"Radiat Oncol"},{"issue":"4","key":"15041_CR48","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.3390\/curroncol29040214","volume":"29","author":"M Buwenge","year":"2022","unstructured":"Buwenge M, Arcelli A, Cellini F, Deodato F, Macchia G, Cilla S, et al. Pain relief after stereotactic radiotherapy of pancreatic adenocarcinoma: an updated systematic review. Curr Oncol. 2022;29(4):2616\u201329.","journal-title":"Curr Oncol"},{"issue":"6","key":"15041_CR49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.prro.2016.05.005","volume":"6","author":"AD Rao","year":"2016","unstructured":"Rao AD, Sugar EA, Chang DT, Goodman KA, Hacker-Prietz A, Rosati LM, et al. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Pract Radiat Oncol. 2016;6(6):417\u201324.","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"15041_CR50","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1186\/s12885-022-10419-4","volume":"22","author":"D Doppenberg","year":"2022","unstructured":"Doppenberg D, Besselink MG, van Eijck CHJ, Intven MPW, Koerkamp BG, Kazemier G, et al. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design. BMC Cancer. 2022;22(1):1363.","journal-title":"BMC Cancer"},{"issue":"1","key":"15041_CR51","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1186\/s12885-023-11327-x","volume":"23","author":"C Bouchart","year":"2023","unstructured":"Bouchart C, Navez J, Borbath IU, Geboes K, Vandamme T, Closset J, et al. Preoperative treatment with mFOLFIRINOX or Gemcitabine\/Nab-paclitaxel +\/- isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial. BMC Cancer. 2023;23(1):891.","journal-title":"BMC Cancer"},{"issue":"3","key":"15041_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S2468-1253(19)30327-9","volume":"5","author":"PA Philip","year":"2020","unstructured":"Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020;5(3):285\u201394.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15041-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15041-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15041-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:02:52Z","timestamp":1761814972000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15041-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15041"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15041-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol has been approved by the central Ethics Committee of the University Hospital Antwerp (Reference ID 5500 -Edge 002715 - BUN B3002023000168 - dated April 8 2024). The study has been approved by each participating institution\u2019s Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TV reports consultancy, advisory roles, honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Elmedix, Ipsen, MyNeoTx, SERB, Novartis, Roche, Sirtex, Servier. Research funding (institutional) from Ipsen and Novartis; support for travel\/accomodation from Ipsen, AstraZeneca, Roche and Servier. The other authors declare that they have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1671"}}